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Translational Discoveries, Personalized Medicine,
and Living Biobanks of the FutureFrom the age of Hippocrates and Galen to the pioneer-
ing work of the likes of Morgagni, Virchow, and count-
less others, pathology remains an absolutely crucial
part of diagnostic medical science. The American So-
ciety of Investigative Pathology describes pathology as
“the medical specialty that provides a scientific foun-
dation for medical practice” (http://www.asip.org/
career/index.htm). The NIH also recognizes the impor-
tance of the intersection between disease understanding
and treatment advancements. With the rapidly changing
field of translational research becoming a top priority for the
NIH, pathology as a discipline demands closer, more syn-
ergistic interactions between the basic and medical re-
search communities. Pathologists contribute fundamen-
tally important expertise in both clinical research and
preclinical modeling for the investigation of all human
diseases, from embryonic development to aging, can-
cer, and dementia. This has been and continues to be
one of the core strengths of academic and medical
pathologists, a strength that is mirrored in the pages of
The American Journal of Pathology.
Pathology’s Contributions
Pathology is not a static discipline relying solely on the
microscopic examination of tissue specimens. It is an
evolving science that continues to incorporate the latest
in scientific methods into its role in the identification and
characterization of human diseases. Newer technologies
such as mass spectrometry, advanced fluorescence-ac-
tivated cell sorting capabilities, high-throughput se-
quencing, and other molecular techniques are changing
the role of the pathologist, increasing our ability to char-
acterize disease, and adding to the complexity of infor-
mation that the discipline of pathology provides to the
medical community.
In addition, the evolving science of obtaining and
interpreting omics data—beyond genomics to tran-
scriptomics, metabolomics, proteomics, and epig-
enomics—to arrive at new markers of disease state,
prognosis, and therapy, as well as insights into the
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thologist must possess an understanding of computa-
tional biology to be an informed consumer of the enor-
mous amount of data contained in a single omics data
set. Pathology, therefore, represents a critical part of
the research enterprise needed to improve health care
and understand disease pathogenesis. It is the disci-
pline, above all others, that provides the bedrock on
which biomedical science progresses.
Pathology in the Ever-Changing World of
Publishing
Journals represent the traditional gatekeeper of high-
quality science within the framework of the highest-
quality expertise in peer review, and this is equally true
for pathology as for other disciplines. Traditional print
journals have been the forum for presenting scientific
advances and for obtaining peer review and input into
scientific inquiry. This model, however, is evolving in
the era of electronic information with electronic jour-
nals, alternative methods of peer review, and wiki-like
discussions of research. This has been coupled with a
proliferation of scientific journals, mainly electronic,
aiding the dissemination of medical information.
The impact factor of many journals is also changing,
owing to this dynamic flux in the publishing landscape.
It is unclear whether the traditional impact factors are
still an accurate measure of the true value of publica-
tion in a particular journal. This is illustrated by the
strong influence of review articles on impact factor
scores. Although reviews can drive dramatic changes
in impact factor and provide an important service to the
research community, the quality of primary science
published in a journal is a truer measure of how suc-
cessful a particular journal is viewed by the scientific
community it serves. Where authors decide to submit
their primary research is paramount to any journal’s
success. For pathology journals, the issue then be-
comes what is the balance of traditional pathological
research and diagnostic methods, together with cut-
ting-edge research and development articles, that pro-
vides what is needed for the modern pathologist?
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stituents, including the membership of the American
Society of Investigative Pathology in the case of
the AJP?
Since I began my service as Editor-in-Chief in 2008,
we have intentionally broadened the scope of the AJP
by accepting more omics articles and articles seeking
to integrate multiple scientific approaches with classi-
cal cellular and morphologic analysis to arrive at new
pathogenic paradigms. As was true of my predeces-
sors, we have continued to solicit high-quality Reviews
and Commentaries. In addition, the AJP again began
receiving Short Communications to facilitate the rapid
publication of cutting-edge short research articles,
which otherwise might be submitted elsewhere. I also
broadened the Associate Editor pool and the editorial
board to include scientists with expertise in emerging
technologies and fields of research. These changes, I
believe, are strongly reflected in the quality of science
published in the AJP and in the high regard for this
journal among research and clinical scientists.
As per the AJP’s scope (http://www.journals.elsevierhealth.
com/periodicals/ajpa/aims), we will continue to “accept
manuscripts on the cellular and molecular biology of
disease that advance the basic and translational
knowledge of the pathogenesis, classification, diagno-
sis, and mechanisms of disease, without preference for
a specific analytic method. Priority will be given to
studies on human disease and relevant experimental
models using cellular, molecular, animal, biological,
chemical, and immunological approaches in conjunc-
tion with morphology.” We will solicit high-quality Re-
views that focus on emerging technologies in pathol-
ogy and that offer a new synthesis of the pathogenesis
of disease. We must be a journal for the next century by
increasing our electronic presence and providing val-
ue-added content that allows dynamic interaction of
the scientific community with the full data content pub-
lished in the AJP.
Continued Emphasis on Translational
Research
To emphasize the value of the translational data pub-
lished in the AJP, we will continue to highlight major
advances reported in our pages. Our Commentary and
press release programs, together with the coordination
of institutional media offices, helps to disseminate the
forward-thinking advances appearing in the AJP and
promotes many of the goals put forth by the NIH and
other national agencies as they relate to translational
medicine with the goal of improving disease diagnosis,
treatment, and prevention.
One such example is the recent article by Liu et al1
on conditionally reprogrammed cells (CRCs) from nor-
mal and cancerous biopsy specimens of human and
rodent tissues. In an elegant series of experiments,Schlegel, Riegel, Albanese, and others at Georgetown
University in collaboration with McBride at the NIH
established a new method for propagating, in vast
numbers, primary breast, prostate, and other types of
differentiated epithelium without the need for passage
through mice or the use of transforming oncogenes.1
Termed the Georgetown Method by Rimm at Yale Uni-
versity in the accompanying Commentary,2 this CRC
culture system enables generation of the first inex-
haustible patient-specific biobank of primary epithelial
cells and cancer cells from the same patient.
This major breakthrough, which was also highli-
ghted in the NCI Cancer Bulletin (http://www.cancer.
gov/ncicancerbulletin/012412/page6, last accessed
February 16, 2012) is timely, indeed, as it addresses the
recent lamentations published in a letter to Nature, where
Hyman and Simons3 clearly articulate the need for gen-
erating more clinically relevant cell lines to allow for com-
pletely rewriting the rules by which human cells are used
in preclinical studies.
One of the most exciting aspects of CRCs is their
adaptability. For example, using this more flexible ap-
proach, CRCs may soon provide for the rapid screen-
ing of tumor cell drug sensitivity using a patient’s own
proliferating cells. Although the Food and Drug Admin-
istration will eventually need to be involved in the ap-
proval of such an approach, the Georgetown Method
combined with phenotypically matched stromal cells
may soon be the basis for truly personalized medicine.
If successful, the CRC/stromal system represents a
critical turning point/change in trajectory away from the
more traditional paradigm of relying on genetic infor-
mation to suggest indirectly possible drug treatments
to a more applied approach of direct sensitivity screen-
ing.
Because the supply of a patient’s cells is now virtu-
ally unlimited, new mechanistic, grafting, and omics
studies can and will be performed to improve our un-
derstanding of the differences between a patient’s nor-
mal and cancerous cells. The living biobank(s) that will
arise from using this technology will also be used for a
variety of basic and applied studies, such as to study
the clonality of tumors. In short, the Georgetown
Method makes possible a bench-to-bedside-and-
back-again approach to personalized medicine on
many different fronts.
A Future Trajectory of Growth
It is a credit to the stature and strength of the AJP that
Liu et al1 chose to submit their groundbreaking work to
our journal. This pioneering work should be widely
cited for many years to come, and I am thrilled that we
had a hand in its peer review and publication. Similarly,
Mori et al,4 led by Mina Bissell at Lawrence Berkeley
National Laboratory, have chosen to publish in the AJP
details of their revolutionary new imaging techniques
for viewing pathology tissue specimens. Please keep
an eye out for this paradigm-shifting work, which is now
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AJP. It is clear that the AJP continues not only to excel
but also to play a major leadership role in publishing
top-tier, cutting-edge research. With the continued
support of our readers and authors, we will maintain
this trajectory well into the future.
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